Dual Trigger With Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin to Optimize ICSI Reproductive Outcomes
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 03 Jun 2016
Price : $35 *
At a glance
- Drugs Triptorelin (Primary) ; Choriogonadotropin alfa
- Indications Infertility
- Focus Therapeutic Use
- 25 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 25 May 2015 Status changed from discontinued to recruiting according to ClinicalTrials.gov record.
- 25 May 2015 Protocol has been amended to increase treatment arms from 2 to 3 and planned number of patients from 400 to 800.